Daniel Fu

Daniel J. Fu is a clinical researcher focused on the development and evaluation of rapid-acting antidepressant therapies, with a particular emphasis on esketamine clinical trials. He has been involved in multiple randomized and phase 3 studies assessing esketamine nasal spray in adults with treatment-resistant depression, pooled analyses of the ASPIRE I and II trials addressing major depressive disorder with active suicidal ideation and intent, and investigations of esketamine use in adolescents at imminent suicide risk. His work spans acute efficacy studies, patient-reported outcomes, flexible-dosing strategies combined with oral antidepressants, and safety/maintenance analyses such as those reported from the ongoing SUSTAIN-3 study.

Fu's contributions are primarily clinical and translational, centred on trial design, outcomes assessment, and the safety profiling of fast-acting glutamatergic interventions in mood disorders. He has co-authored randomized, controlled trials and pooled analyses that have informed regulatory and clinical discussions about the role of esketamine in treating severe and suicidal depression, and has contributed to the evidence base for both monotherapy and adjunctive use in diverse adult and adolescent populations.